



## FOR IMMEDIATE RELEASE

CONTACT:  
Zamas Lam  
VP of Non-Clinical Development  
[zamas.lam@qps-usa.com](mailto:zamas.lam@qps-usa.com)  
Phone: 302.369.5117

### QPS Announces New Fellow of Autoradiography

**(NEWARK, DE; April 6, 2010)** – [QPS](#), a leading full-service GLP/GCP-compliant contract research organization (CRO) providing testing services to support preclinical and clinical research and development, is pleased to announce today the appointment of Eric G. Solon, Ph.D., to the position of Fellow, Autoradiography DMPK.

QPS CEO and Founder, Ben Chien, Ph.D., said, “I am thrilled with Eric’s appointment to our first scientific track position. Eric is widely regarded as one of the industry’s leading experts in pioneering the use of autoradiography in drug discovery and development. In fact, one of his recent microautoradiography photos was featured in [Fox News’ The Best Science Photo of the Week](#). His new assignment will continue to sharpen QPS’ focus on the innovative use of technology, such as microautoradiography and xenograft, to identify new opportunities that help our clients accelerate their drug discovery and development programs.”

Dr. Solon has been serving as the Director of Autoradiography for QPS since 2002. Prior to joining QPS, Dr. Solon served as one of the DMPK representatives of the anti-viral project team at DuPont Pharmaceuticals. He coordinated preclinical ADME activities for ERC and IND filings and implemented both macro- and microautoradiography techniques. Before joining DuPont, he held various scientific posts in toxicology/pathology and DMPK at Ciba-Geigy Pharmaceuticals, Novartis and Schering-Plough Research Institute. Dr. Solon received his Ph.D. in molecular biology/pathology from Rutgers University. He is currently the president *ex officio* and a course instructor for the Society for Whole-Body Autoradiography and an *ad hoc* consultant for AAALAC International.

-more-

"QPS' reputation as a quality CRO has been growing consistently since its inception. The addition of a scientific track to support the discovery and development of both small molecules and biologic drugs shows a true focus on science and service," said Dr. Solon. "QPS has been heavily involved in the development of monoclonal antibodies and oligonucleotide-based drugs. This new assignment is another commitment to the ongoing DMPK expansion in the biologics arena. I look forward to continue working with my colleagues on autoradiography, as well as playing a role in developing new opportunities to help our clients."

**About QPS**

QPS provides GLP/GCP-compliant preclinical and clinical research services to pharmaceutical and biotechnology clients worldwide in the areas of bioanalysis, DMPK, translational medicine research and early-phase clinical research. Our regional laboratories are located at Newark, Delaware; Springfield, Missouri; and Taipei, Taiwan. To learn more about QPS, visit [www.qps-usa.com](http://www.qps-usa.com).

###